Analysis of cell cycle regulator proteins in encapsulated thymomas

Clinical Cancer Research

Volumn 11, Issue 14, 2005, Pages 5078-5083

  Baldi, Alfonso ^c   Ambrogi, Vincenzo ^a   Mineo, Davide ^a   Mellone, Pasquale ^c   Campioni, Mara ^c   Citro, Gennaro ^b   Mineo, Tommaso Claudio ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CYCLE PROTEIN; PROTEIN P21; PROTEIN P27; PROTEIN P53;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CELL CYCLE; CELL GROWTH; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENCAPSULATION; FEMALE; FOLLOW UP; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECURRENCE RISK; THYMOMA;

ADOLESCENT; ADULT; AGED; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; SURVIVAL ANALYSIS; THYMOMA; THYMUS NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 22344456348     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0070     Document Type: Article

References (23)

1. Masaoka A, Monden Y, Nakahara K, Tanioka T, Follow-up study of thymomas with special reference to their clinical stages. Cancer 1981;48: 2485-92.
2. Wilkins KB, Sheikh E, Green R, et al. Clinical and pathologic predictors of survival in patients with thymoma. Ann Surg 1999;230:562-72.
3. Strobel P, Bauer A, Puppe B, et al. Tumor recurrence and survival in patients treated for thymomas and thymic squamous cell carcinomas: a retrospective analysis. J Clin Oncol 2004;22:1501-9.
4. Sherr CS. Cancer cell cycles. Science 1996;274: 1672-7.
5. Grana X, Reddy EP. Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors. Oncogene 1995;11:211-9.
6. Kirsch DG, Kastan MB. Tumor-suppressor p53: implications for tumor development and prognosis. J Clin Oncol 1998;16:3158-68.
7. Hirabayashi H, Fuji Y, Sakaguchi M, et al. p16, pRB, p53 and cyclin D1 expression and hypermethylation of CDKN2 gene in thymoma and thymic carcinoma. Int J Cancer 1997;73:639-44.
8. Stefanaki K, Rontogianni D, Kouvidou CH, et al. Expression of p53, mdm2, p21/waf1 and bcl-2 proteins in thymomas. Histopathology 1997;30:549-55.
9. Rosai J. Histological typing of tumors of the thymus. In: WHO international histological classification of tumors. New York: Springer-Verlag: 1999. p. 80-95.
10. Hiroshijma K, Iyoda A, Toyozaki T, et al. Proliferative activity and apoptosis in thymic epithelial neoplasms. Mod Pathol 2002;15:1326-32.
11. Pan CC, Chen CH, Wang LS, Lee JY, Chiang H. Expression of apoptosis-related markers and HER-2/neu in thymic epithelial tumours. Histopathology 2003;43: 165-72.
12. Kohman LJ. Controversies in the management of malignant thymoma. Chest 1997;112:296-300S.
13. Nakagawa K, Asamura H, Matsuno Y, et al. Thymoma: a clinicopathologic study based on the new WHO classification. J Thorac Cardiovasc Surg 2003; 126:1134-40.
14. Okumura M, Ohta M, Tateyama H, et al. The World Health Organization histologic classification system reflects the oncologic behavior of thymoma. Cancer 2002;94:624-32.
15. Blumberg D, Port JL, Weksler B, et al. Thymoma-a multivariate analysis of factors predicting survival. Ann Thorac Surg 1995;60:908-13.
16. Regnard J-F, Magdeleinat P, Dromer C. Prognostic factors and long-term results after thymoma resection-a series of 307 patients. J Thorac Cardiovasc Surg 1996;112:376-84.
17. Wilkins KB, Sheikh E, Green R, et al. Clinical and pathologic predictors of survival in patients with thymoma. Ann Surg 1999;230:562-72.
18. Esposito V, Baldi A, De Luca A, et al. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non small cell lung cancer. Cancer Res 1997;57: 3381-5.
19. Baldi A, Santini D, Vasaturo F, et al. Prognostic significance of cyclooxygenase-2 (COX-2) and expression of cell cycle inhibitors p21 and p27 in human pleural malignant mesothelioma. Thorax 2004;59: 428-33.
20. Takahashi S, Kamata Y, Tamo W, et al. Relationship between postoperative recurrence and expression of cyclin E, p27 and Ki-67 in non-small cell lung cancer without lymph node metastases. Int J Clin Oncol 2002;7:349-55.
21. Halvorsen OJ, Haukaas SA, Akslen LA. Combined loss of PTEN and p27 expression is associated with tumor cell proliferation by KI-67 and increased risk of recurrent disease in localized prostate cancer. Clin Cancer Res 2003;9:1474-9.
22. McCallum M, Baker C, Gillispie K, et al. A prognostic index for operable, node-negative breast cancer. Br J Cancer 2004;90:1933-41.
23. Franklin DS, Godfrey VL, O'Brien DA, et al. Functional collaboration between different cyclin-dependent kinase inhibitors suppresses tumor growth with distinct tissue specificity. Mol Cell Biol 2000;20: 6147-58.